RxDoctor Payments Data

Michaelle Halaby Holmes, MD

Internal Medicine · Pikesville, MDNPI 1932105137

Payments from drug & device makers

$16,400in general payments, 2019–2025

Across 756 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • GSK$1K
  • AbbVie$1K
  • Amgen$1K
  • Pfizer$957
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$16,24699%
  • Education$1541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,400 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$152,267
Medicare patients
424
Services billed
2,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$80,450
EliquisApixaban42$44,789
JanuviaSitagliptin Phosphate22$31,218
Janumet XrSitagliptin Phos/Metformin Hcl41$29,920
JardianceEmpagliflozin19$28,201
FarxigaDapagliflozin Propanediol31$23,948
JanumetSitagliptin Phos/Metformin Hcl19$21,123
Xigduo XrDapaglifloz Propaned/Metformin14$16,130
XareltoRivaroxaban24$15,514
Tresiba Flextouch U-200Insulin Degludec11$10,643
Breo ElliptaFluticasone/Vilanterol18$8,764
Atorvastatin Calcium426$8,138
Rosuvastatin Calcium253$6,771
Amlodipine Besylate374$4,201
Solifenacin Succinate29$3,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr, Janumet$462$82,26082 claims
Novo NordiskOzempic$3,015$80,45063 claims
PfizerEliquis$957$44,78942 claims
Boehringer IngelheimJardiance$648$28,20119 claims
AstraZenecaFarxiga$1,527$23,94831 claims
Johnson & JohnsonXarelto$198$15,51424 claims
GSKBreo Ellipta$1,209$8,76418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Pikesville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →